Clinical trials: Pulmonary Hypertension, Primary
Pulmonary Artery Hypertension
Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension
The primary objective of this study is to determine the impact of two interventions against insulin resistance on the composite endpoint of 10% improvement in baseline six minute walk distance or improvement in World Health…
- Trial name
- NCT03617458
- Testing
- Metformin, mHealth Intervention, Usual Care
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Arterial Hypertension
Pulmonary Hypertension: Intensification and Personalisation of Combination Rx
The goal of this clinical trial is to evaluate the capacity of implantable/remote technology for early evaluation of drug therapies in patients with pulmonary arterial hypertension (PAH).
- Trial name
- PHoenix (NCT05825417)
- Testing
- Selexipag, Riociguat, CardioMEMS pulmonary artery pressure monitor
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Pulmonary Arterial Hypertension, Acute Respiratory Failure
Efficacy and Safety of High-Flow Nasal Cannula Versus Noninvasive Ventilation for Pulmonary Arterial Hypertension-Associated Acute Respiratory Failure
This is a single center, retrospective, propensity score matching cohort study that explores the efficacy and safety of high flow nasal cannula and non-invasive ventilation in the treatment of acute respiratory failure associated…
- Conditions
- Pulmonary Arterial Hypertension, Acute Respiratory Failure, High-flow Nasal Cannula, Noninvasive Ventilation
- Trial name
- HFCNV-PAH (NCT06582459)
- Testing
- HFNC treatment, NIV treatment
- Where
- China
- Volunteers
- 90 people
- Sponsor
- The First People's Hospital of Neijiang
Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Assessment of Blood Coagulation Disorders in Patients With Pulmonary Hypertension
The objective of the present study is to assess blood coagulation disorders in patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension.
- Trial name
- NCT03195543
- Testing
- Platelet function analyzer-100, Light transmission aggregometry, Rotational thromboelastometry
- Where
- Greece
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National and Kapodistrian University of Athens
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Biomarkers in the Evaluation of Chronic Lung Disease
We hypothesize that hypoxia-induced pulmonary vascular remodeling is mediated by macrophage migration inhibitory factor (MIF), that remodeling is in fact the reflection of a chronic inflammatory process, and that MIF may be a…
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Interstitial Lung Disease
- Trial name
- NCT00926523
- Testing
- Blood Gas, Pulmonary Exercise Test, Spirometry
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Pulmonary Arterial Hypertension
Evaluation of the Role of Epstein-Bar Virus in Patients With Pulmonary Arterial Hypertension
Evaluate the role of Epstein-Barr virus infection in PAH (Idiopathic and connective tissue disease). This by obtaining a blood sample from the PAH patients undergoing right heart cathetrization as well as obtaining the…
- Trial name
- NCT06550648
- Testing
- Right Heart Catheterization (Swan Ganz Catheter)
- Where
- Egypt
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Cairo University
Hypertension, Pulmonary
Multidisciplinary Collaboration Care in Pulmonary Arterial Hypertension (PAH)
Pulmonary arterial hypertension (PAH) is a severe pulmonary vascular affection, which treatment has evolved in the last few years, improving quality of life. However, adherence to treatment has not been assessed in such patients.
- Trial name
- ETHAP (NCT01038284)
- Testing
- Patient education, Data collection
- Where
- 11 sites in France
- Volunteers
- 101 people
- Sponsor
- University Hospital, Grenoble
Pulmonary Arterial Hypertension
A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension
A Randomized, Placebo-Controlled, Double-blind, Dose Escalation Study to Assess Safety, Efficacy and Pharmacokinetics of GMA301 Injection in Subjects with Pulmonary Arterial Hypertension
- Trial name
- NCT04503733
- Testing
- Q4W GMA301 IV injections (300 mg), Q4W GMA301 IV injections (600 mg), Q4W GMA301 IV injections (1000 mg)
- Where
- 7 sites in United States, China
- Volunteers
- 48 people
- Sponsor
- Gmax Biopharm LLC.
Pulmonary Arterial Hypertension
Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)
This is a 12-week, international, multicenter, double-blind, three-group, dose-response study to assess the safety and efficacy of BPS-MR in patients with PAH.
- Trial name
- NCT00989963
- Testing
- Beraprost Sodium Modified Release
- Where
- 17 sites in United States, Belgium and 4 more
- Volunteers
- 36 people
- Sponsor
- Lung Biotechnology PBC
Pulmonary Arterial Hypertension
Oral Iron Supplementation in Pulmonary Hypertension
The purpose of this study is to investigate the effects of iron supplementation in patients with pulmonary arterial hypertension and iron deficiency.
- Trial name
- NCT01446848
- Testing
- iron supplement
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- The Cleveland Clinic
Systemic Sclerosis-Associated PAH
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) is a serious, life-threatening manifestation of systemic sclerosis (SSc), an autoimmune disease of the connective tissue characterized by scarring (fibrosis)…
- Trial name
- NCT01086540
- Testing
- Rituximab, CMRI, prednisone
- Where
- 17 sites in United States
- Volunteers
- 57 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pulmonary Arterial Hypertension
Beraprost-314d Added-on to Tyvaso® (BEAT)
This is a multicenter, double-blind, randomized, placebo-controlled Phase 3 study, to assess the efficacy and safety of BPS-314d-MR when added-on to inhaled treprostinil (Tyvaso®)in patients with pulmonary arterial hypertension.
- Trial name
- BEAT (NCT01908699)
- Testing
- Beraprost Sodium 314d Modified Release Tablets
- Where
- 75 sites in United States, Israel
- Volunteers
- 273 people
- Sponsor
- Lung Biotechnology PBC
Pulmonary Arterial Hypertension
A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)
IMPAHCT: Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial is a Phase 2b/Phase 3 study to evaluate the safety and efficacy of AV-101 (dry powder inhaled imatinib) in patients with Pulmonary Arterial Hypertension…
- Trial name
- IMPAHCT (NCT05036135)
- Testing
- AV-101
- Where
- 128 sites in United States, Argentina and 24 more
- Volunteers
- 202 people
- Sponsor
- Aerovate Therapeutics
Pulmonary Arterial Hypertension
ACT-293987 in Pulmonary Arterial Hypertension
Long-term, single-arm, multicenter, open-label extension, Phase 3 study, to evaluate the safety and tolerability of ACT-293987 in patients with PAH who participated in the double-blind study AC-065A302 (GRIPHON)
- Trial name
- NCT01112306
- Testing
- ACT-293987
- Where
- 157 sites in United States, Argentina and 36 more
- Volunteers
- 709 people
- Sponsor
- Actelion
Hypertension, Pulmonary
BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension
Patients who have completed the 12 weeks treatment of the PATENT-1 trial (study number 12934) will be asked to participate in this long term extension study with BAY63-2521.
- Trial name
- PATENT-2 (NCT00863681)
- Testing
- Riociguat (BAY63-2521)
- Where
- 99 sites in United States, Argentina and 25 more
- Volunteers
- 396 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Crossover Study From Macitentan or Bosentan Over to Ambrisentan
The purpose of this study is to learn more about the safety and effects of switching treatments from bosentan (Tracleer) or macientan (Opsumit) to ambrisentan (Letairis) over 24 weeks in subjects with Connective Tissue Disease…
- Trial name
- Letairis (NCT02885012)
- Testing
- Ambrisentan
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Medical University of South Carolina
Hypertension, Pulmonary, Pulmonary Arterial Hypertension
Effect of Food on the Pharmacokinetics of Oral Treprostinil
The purpose of this study is to assess the pharmacokinetic and safety profile of a single dose of oral treprostinil following four different meals of varying caloric and fat content.
- Trial name
- NCT00963001
- Testing
- Treprostinil diethanolamine, Standardized meals
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
Repeatability of OCT and IV-US in Pulmonary Arterial Hypertension
To assess the correlation between pulmonary IV-OCT and pulmonary IV-US measurements and standard PAH clinical measures of disease progression and the relative sensitivity of the techniques to change.
- Trial name
- NCT03105934
- Testing
- Patients with Pulmonary Arterial Hypertension
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Hypertension, Pulmonary, Pulmonary Arterial Hypertension
Endothelial Function in Patients With Pulmonary Arterial Hypertension
The objectives of the current study are to identify and evaluate new prognostic non-invasive and serological markers in patients with pulmonary hypertension.
- Conditions
- Hypertension, Pulmonary, Pulmonary Arterial Hypertension, Pathophysiology, Genetics
- Trial name
- NCT01317134
- Testing
- EndoPAT measurement, Blood Test
- Where
- Germany
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Pulmonary Arterial Hypertension
A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)
The purpose of this study is to assess the safety and efficacy of Rodatristat Ethyl in pulmonary arterial hypertension (PAH) patients.
- Trial name
- NCT04712669
- Testing
- rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID
- Where
- 64 sites in United States, Austria and 15 more
- Volunteers
- 108 people
- Sponsor
- Altavant Sciences GmbH